For instance, the inhibitors of CDK4/6 have been approved for the treatment of breast cancer [29], and inhibitors of HSP90 (geldanamycin (GA), radicicol (RD), and its semisynthetic derivatives) were in preclinical research of tumor [41]. This evidence concerns the gene HSP90AA1 and neoplasm.